Dianthus Therapeutics (Dianthus Therapeutics) Short-Term Capital Lease Obligation : $0.40 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Short-Term Capital Lease Obligation?

Dianthus Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.40 Mil.

Dianthus Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($0.41 Mil) to Dec. 2023 ($0.42 Mil) but then declined from Dec. 2023 ($0.42 Mil) to Mar. 2024 ($0.40 Mil).

Dianthus Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.35 Mil) and increased from Dec. 2022 ($0.35 Mil) to Dec. 2023 ($0.42 Mil).

Dianthus Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Dianthus Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Short-Term Capital Lease Obligation Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.35

0.42

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial			0.35	-	0.41	0.42	0.40

Dianthus Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Dianthus Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023